Vertex Pharmaceuticals VRTX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $3.95B— | —— | $3.62B+9.0% | $3.32B+41.8% | ||
| $209.8M+1.3% | $207.2M+14.3% | $181.3M+22.3% | $148.3M+18.1% | ||
| $685.9M-1.8% | $698.5M+20.2% | $581.2M+18.3% | $491.3M+11.3% | ||
| $347.3M— | —— | $120.53M-67.3% | $368.8M— | ||
| $524.2M+1.3% | $517.3M+60.2% | $322.9M+137% | $136.4M+47.0% | ||
| $36.8M-25.7% | $49.5M-46.6% | $92.68M-23.3% | $120.8M+279% | ||
| $148.5M— | —— | $208.9M-58.1% | $498.9M+2,870% | ||
| $3.63B+235% | -$2.69B-176% | $3.54B-14.3% | $4.13B+45.3% | ||
| $437.6M+47.0% | $297.7M+48.6% | $200.4M-2.1% | $204.7M-12.9% | ||
| $6.4B-14.0% | $7.44B+96.4% | $3.79B+447% | $692.7M+31.1% | ||
| -$945.4M+74.9% | -$3.77B-20.0% | -$3.14B— | —— | ||
| $2.02B+71.4% | $1.18B+175% | $427.6M— | $0-100% | ||
| $369.9M-8.7% | $405M+79.1% | $226.1M+31.5% | $172M+26.6% | ||
| -$2.26B-51.3% | -$1.49B-158% | -$579.5M— | —— | ||
| $95M+323% | -$42.6M-258% | $26.9M— | —— | ||
| $549.8M— | —— | -$1.03B-128% | $3.71B— | ||
| $12.4M-59.3% | $30.5M-29.2% | $43.1M-17.6% | $52.3M-7.1% | ||
| $379M— | $0— | $0— | —— | ||
| -$116.9M— | —— | $893.45M— | —— | ||
| $396M— | —— | $545.7M+67.2% | $326.4M— | ||
| -$120.1M-13,244% | -$900K-102% | $42.6M+461% | -$11.8M— | ||
| $25.5M-52.8% | $54M+122% | $24.35M-49.1% | $47.8M— | ||
| $5.9B+32.1% | $4.47B+432% | $839.1M— | —— | ||
| $127.7M+11.4% | $114.6M-14.9% | $134.6M-27.8% | $186.3M+82.6% | ||
| $3.7M-40.3% | $6.2M+65.3% | $3.75M+7.1% | $3.5M-38.6% | ||
| $1.57B+44.8% | $1.08B-35.5% | $1.68B+58.6% | $1.06B+122% | ||
| $0— | $0-100% | $180M— | $0— | ||
| $3.19B+207% | -$2.98B-189% | $3.34B-15.0% | $3.93B— | ||
| $3.19B+207% | -$2.98B-189% | $3.34B-15.0% | $3.93B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vertex Pharmaceuticals generate?
- Vertex Pharmaceuticals (VRTX) generated $4.2B in operating cash flow over the trailing twelve months.
- What is Vertex Pharmaceuticals's free cash flow?
- After $530.3M of capital expenditures, Vertex Pharmaceuticals's free cash flow was $3.7B over the trailing twelve months, up 207.9% year over year.
- Where does Vertex Pharmaceuticals's cash flow data come from?
- Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
